Review Article
Volume 5 Issue 3 - 2021
Requirements for Insulin Glargine 300 U/Ml for Patients with Type-1 Diabetes Mellitus Previously Treated with Insulin Glargine 100 U/Ml, According to the Number of Daily Injections Given Previously
Mercè Albareda*, Mercè Lara, Raquel Barnés, Yolanda Torres, Gemma Francisco and Lluís Vila
Endocrinology Department, Hospital de Sant Joan Despí Moisés Broggi, Consorci Sanitari Integral, Barcelona, Spain
*Corresponding Author: Mercè Albareda, Endocrinology Department, Hospital de Sant Joan Despí Moisés Broggi, Consorci Sanitari Integral, Barcelona, Spain.
Received: January 12, 2021; Published: February 22, 2021


Aims: To assess the requirement for insulin glargine 300 U/mL (Gla-300) in people with Type 1 diabetes mellitus (Type 1 DM) previously treated with glargine 100 U/mL (Gla-100), depending on the prior number of daily injections of insulin. The secondary goal is to observe the differences in HbA1c and hypoglycaemia after 6 months of treatment with Gla-300.

Methods: Cross-sectional observational study of people with type 1 DM treated with basal-bolus therapy. Group 1: participants treated with a single dose of insulin Gla-100. Group 2: participants treated with two doses a day. Following medical criteria, all subjects were switched to insulin Gla-300.

Results: 133 participants with type 1 DM: 73 in Group 1 and 60 in Group 2. The participants in Group 2 required a significantly higher dose of basal insulin than those in Group 1, both on a baseline level and at 6 months. No differences in mealtime insulin were observed. There was a significantly increase in insulin dose of Gla-300 than previous doses of Gla-100 in both groups: 18.2% in Group 1 vs 6.4% in Group 2 (p < 0.001). No changes in HbA1c were observed in the two groups at 6 months of treatment and there was a significant reduction in hypoglycaemia in Group 1 (6 vs 4 per month).

Conclusion: Group 2 participants needed a lower increase in their dose of insulin on switching to Gla-300 than subjects in Group 1. The subjects in Group 1 presented less hypoglycaemia after switching treatment, without changes in HbA1c levels.


Keywords: Type 1 Diabetes; Insulin Glargine; Basal-Bolus Therapy; Hypoglycaemia


  1. Lepore M., et al. “Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultra lente human insulin and continuous subcutaneous infusion of lispro”. Diabetes 49 (2000): 2142-2148.
  2. Ashwell SG., et al. “Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart”. Diabetic Medicine 23 (2006): 879-886.
  3. Albright ES., et al. “Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy”. Diabetes Care 27 (2004): 632-633.
  4. Clement S and Bowen-Wrigt H. “Twenty-four-hour action of insulin glargine (Lantus) may be too short for once-daily dosing: A case report”. Diabetes Care 25 (2002): 1479-1480.
  5. Becker RH., et al. “New insulin glargine 300 units. mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units.mL-1”. Diabetes Care 38 (2015): 637-643.
  6. Home PD., et al. “New insulin glargine 100 Units/mL in people with type 1 diabetes: A randomized, phase 3a, open-label clinical trial (EDITION 4)”. Diabetes Care 38 (2015): 2217-2225.
  7. Matsuhisa M., et al. “New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)”. Diabetes, Obesity and Metabolism 18 (2016): 375-383.
  8. Heinemann L., et al. “Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo”. Diabetes 23 (2000): 644-649.
  9. Gradiser M., et al. “Changes in HbA1c and hypoglycemic episodis in type 1 diabetes patients after switching to insulin glargine 300: Pilot study”. Diabetes Research and Clinical Practice 129 (2017): 144-147.
  10. Pang T., et al. “A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA)”. Diabetic Medicine 36 (2019): 110-119.
  11. Pujante-Alarcón P., et al. “Experience after switching from insulin glargine U100 to glargine U300 in patients with type 1 diabetes mellitus. A study after one year of treatment in real life”. Endocrinología, Diabetes y Nutrición 66 (2019): 210-216.
  12. Oriot P. “Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/mL to glargine 300 U/mL in real life”. Expert Review of Endocrinology and Metabolism 13 (2018): 167-171.
  13. Ritzel R., et al. “Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes”. Diabetes, Obesity and Metabolism 17 (2015): 859-867.
  14. De Galan BE. “Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives”. Patient Preference and Adherence 10 (2016): 2097-2106.
Citation: Mercè Albareda., et al. “Requirements for Insulin Glargine 300 U/Ml for Patients with Type-1 Diabetes Mellitus Previously Treated with Insulin Glargine 100 U/Ml, According to the Number of Daily Injections Given Previously”. EC Diabetes and Metabolic Research 5.3 (2021): 02-09.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

November Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 15, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.